Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity.
暂无分享,去创建一个
C. Ross | A. Sawa | T. Dawson | V. Dawson | Wanli W. Smith | Z. Pei | Yuji Tanaka | H. Morita | Haibing Jiang
[1] A. Kanthasamy,et al. Wild-type α-synuclein interacts with pro-apoptotic proteins PKCδ and BAD to protect dopaminergic neuronal cells against MPP+-induced apoptotic cell death , 2005 .
[2] N. Fullwood,et al. The production of hydrogen peroxide during early-stage protein aggregation: a common pathological mechanism in different neurodegenerative diseases? , 2005, Biochemical Society transactions.
[3] Andreas Hald,et al. Oxidative stress and inflammation in Parkinson's disease: is there a causal link? , 2005, Experimental Neurology.
[4] M. Feany,et al. α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease , 2005, Nature Neuroscience.
[5] M. Gorospe,et al. Phosphorylation of p66Shc and forkhead proteins mediates Aβ toxicity , 2005, The Journal of cell biology.
[6] H. Federoff,et al. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease? , 2005, Brain research. Molecular brain research.
[7] Junying Yuan,et al. A Selective Inhibitor of eIF2α Dephosphorylation Protects Cells from ER Stress , 2005, Science.
[8] E. Bennett,et al. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. , 2005, Molecular cell.
[9] T. Sherer,et al. Ubiquitin–proteasome system and Parkinson's diseases , 2005, Experimental Neurology.
[10] C. Olanow,et al. Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress , 2004, Journal of Neural Transmission.
[11] T. Iwatsubo,et al. Overexpression of α‐synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of α‐synuclein and activation of caspase‐9: resemblance to pathogenetic changes in Parkinson's disease , 2004, Journal of neurochemistry.
[12] D. Perl,et al. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease , 2004, Annals of neurology.
[13] C. Ross,et al. Protein aggregation and neurodegenerative disease , 2004, Nature Medicine.
[14] Coleman Mp,et al. Programmed axon death, synaptic dysfunction and the ubiquitin proteasome system. , 2004 .
[15] D. Xue,et al. To live or die by the sword: the regulation of apoptosis by the proteasome. , 2004, Developmental cell.
[16] J. Hoenicka,et al. The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.
[17] R. Dodd,et al. Oxidative Damage to the Endoplasmic Reticulum is Implicated in Ischemic Neuronal Cell Death , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[18] R. Vento,et al. Apoptosis meets proteasome, an invaluable therapeutic target of anticancer drugs. , 2003, The Italian journal of biochemistry.
[19] L. Stefanis,et al. Ubiquitinated inclusions and neuronal cell death. , 2003, Histology and histopathology.
[20] H. Ischiropoulos,et al. Oxidative stress and nitration in neurodegeneration: cause, effect, or association? , 2003, The Journal of clinical investigation.
[21] P. Lockhart,et al. Parkin Protects against the Toxicity Associated with Mutant α-Synuclein Proteasome Dysfunction Selectively Affects Catecholaminergic Neurons , 2002, Neuron.
[22] Richard Paylor,et al. Synaptic Vesicle Depletion Correlates with Attenuated Synaptic Responses to Prolonged Repetitive Stimulation in Mice Lacking α-Synuclein , 2002, The Journal of Neuroscience.
[23] Robert Burke,et al. Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[24] P. Lansbury,et al. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. , 2002, Journal of molecular biology.
[25] Patrik Brundin,et al. Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. , 2002, Human molecular genetics.
[26] N. Hattori,et al. Effect of Wild-type or Mutant Parkin on Oxidative Damage, Nitric Oxide, Antioxidant Defenses, and the Proteasome* , 2002, The Journal of Biological Chemistry.
[27] Nancy A. Jenkins,et al. Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[28] Bruce A. Yankner,et al. Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.
[29] D. Allsop,et al. Formation of hydrogen peroxide and hydroxyl radicals from Aβ and α-synuclein as a possible mechanism of cell death in Alzheimer’s disease and Parkinson’s disease. , 2002 .
[30] John Q. Trojanowski,et al. Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.
[31] L. Greene,et al. Expression of A53T Mutant But Not Wild-Type α-Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death , 2001, The Journal of Neuroscience.
[32] L. Ellerby,et al. Coupling Endoplasmic Reticulum Stress to the Cell Death Program , 2001, The Journal of Biological Chemistry.
[33] D. Allsop,et al. alpha-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. , 2001, Free radical biology & medicine.
[34] C. Ross,et al. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. , 2001, Human molecular genetics.
[35] K. O’Malley,et al. The Parkinsonism-inducing Drug 1-Methyl-4-phenylpyridinium Triggers Intracellular Dopamine Oxidation , 2000, The Journal of Biological Chemistry.
[36] M. Farrer,et al. Sensitization of Neuronal Cells to Oxidative Stress with Mutated Human α‐Synuclein , 2000 .
[37] J. Keller,et al. Dopamine induces proteasome inhibition in neural PC12 cell line. , 2000, Free radical biology & medicine.
[38] J. Trojanowski,et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.
[39] J. Mallet,et al. Rat α‐Synuclein Interacts with Tat Binding Protein 1, a Component of the 26S Proteasomal Complex , 2000 .
[40] Sarah J. Tabrizi,et al. Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity , 2000 .
[41] T. Dawson,et al. Oxidative Stress and Genetics in the Pathogenesis of Parkinson's Disease , 2000, Neurobiology of Disease.
[42] A. Davies,et al. Induction of neuronal death by α‐synuclein , 2000, The European journal of neuroscience.
[43] D. Ron,et al. Perk is essential for translational regulation and cell survival during the unfolded protein response. , 2000, Molecular cell.
[44] Guido Kroemer,et al. Mitochondrial control of cell death , 2000, Nature Medicine.
[45] B. Giasson,et al. Dityrosine cross-linking promotes formation of stable α-synuclein polymers , 2000, Neurobiology of Aging.
[46] Y. Yang,et al. Enhanced vulnerability to oxidative stress by α-synuclein mutations and C-terminal truncation , 2000, Neuroscience.
[47] W. Bender,et al. A Drosophila model of Parkinson's disease , 2000, Nature.
[48] C. Haass,et al. Neurodegenerative diseases: Parkinson's pathology in a fly , 2000, Nature.
[49] Heidi Phillips,et al. Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.
[50] Junying Yuan,et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β , 2000, Nature.
[51] T. Peng,et al. Mitochondrial dysfunction in Parkinson's disease. , 1999, Biochemical Society symposium.
[52] L. Petrucelli,et al. α-Synuclein Shares Physical and Functional Homology with 14-3-3 Proteins , 1999, The Journal of Neuroscience.
[53] R. Jakes,et al. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α‐synuclein protein implicated in Parkinson's disease , 1998, FEBS letters.
[54] S. Tabrizi,et al. Mitochondria in the etiology and pathogenesis of parkinson's disease , 1998, Annals of neurology.
[55] David F. Clayton,et al. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease , 1998, Trends in Neurosciences.
[56] E. Floor,et al. Increased Protein Oxidation in Human Substantia Nigra Pars Compacta in Comparison with Basal Ganglia and Prefrontal Cortex Measured with an Improved Dinitrophenylhydrazine Assay , 1998, Journal of neurochemistry.
[57] C D Marsden,et al. Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8‐Hydroxyguanine Levels in Substantia Nigra , 1997, Journal of neurochemistry.
[58] A. Lees,et al. A Generalised Increase in Protein Carbonyls in the Brain in Parkinson's but Not Incidental Lewy Body Disease , 1997, Journal of neurochemistry.
[59] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[60] G. Kroemer,et al. Mitochondrial permeability transition is a central coordinating event of apoptosis , 1996, The Journal of experimental medicine.
[61] L. Forno,et al. Neuropathology of Parkinson's Disease , 1996, Journal of neuropathology and experimental neurology.
[62] P. Bernardi,et al. Interactions of Cyclophilin with the Mitochondrial Inner Membrane and Regulation of the Permeability Transition Pore, a Cyclosporin A-sensitive Channel (*) , 1996, The Journal of Biological Chemistry.
[63] D L Evans,et al. Analysis and discrimination of necrosis and apoptosis (programmed cell death) by multiparameter flow cytometry. , 1992, Biochimica et biophysica acta.
[64] J. Sambrook,et al. The presence of malfolded proteins in the endoplasmic reticulum signals the induction of glucose-regulated proteins , 1988, Nature.
[65] A. Kanthasamy,et al. Wild-type alpha-synuclein interacts with pro-apoptotic proteins PKCdelta and BAD to protect dopaminergic neuronal cells against MPP+-induced apoptotic cell death. , 2005, Brain research. Molecular brain research.
[66] M. Feany,et al. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. , 2005, Nature neuroscience.
[67] J. Trojanowski,et al. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. , 2002, Science.
[68] D. Allsop,et al. Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. , 2002, Free radical biology & medicine.
[69] D. Price,et al. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[70] R. Kopito,et al. Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.
[71] M. Farrer,et al. Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein. , 2000, Journal of neurochemistry.
[72] D. Nijhawan,et al. Apoptosis in neural development and disease. , 2000, Annual review of neuroscience.
[73] Y. Yang,et al. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. , 2000, Neuroscience.
[74] J. Mallet,et al. Rat alpha-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex. , 2000, Journal of neurochemistry.
[75] S. Tabrizi,et al. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. , 2000, Human molecular genetics.
[76] A. Strasser,et al. Apoptosis signaling. , 2000, Annual review of biochemistry.
[77] D. Sulzer,et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. , 2000, Neuron.
[78] P Choi,et al. alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. , 1999, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[79] R. Krüger,et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.
[80] S E Ide,et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.